API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Advacan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Lifesciences
Deal Size: $43.8 million Upfront Cash: Undisclosed
Deal Type: Divestment November 09, 2023
Details:
The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): n.c.a. 177Lu-Edotreotide,Everolimus
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Temasek
Deal Size: $272.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 05, 2023
Details:
Everolimus tablets, a generic version of Afinitor® have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet used to treat certain types of cancers and tumours.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Everolimus is the generic name for the trade name drug Afinitor. Breckenridge has launched 10mg strength of Everolimus Tablets used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2021
Details:
Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.
Lead Product(s): Xentuzumab,Everolimus,Exemestane
Therapeutic Area: Oncology Product Name: BI 836845
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2021
Details:
Breckenridge plans to launch Everolimus Tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021 in a blister card packaging configuration.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE).
Lead Product(s): Lenvatinib,Everolimus
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).
Lead Product(s): Everolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus enrolled 31 patients with unresectable advanced or metastatic nccRCC.
Lead Product(s): Lenvatinib,Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2020